Investigational Pharmacy Service at BMC



"Everything you always wanted to know about IPS but were afraid to ask."

Stephen Zalewski, PharmD, CCRC

Objectives

- 1. Define the role of the Investigational Pharmacy Service at BMC.
- 2. Understand how to engage the services offered.
- 3. Identify general project timelines for drug studies at BU/BMC.

What is the Role of IPS at BMC?

- The Investigational Pharmacy Service is one of the many services offered by the Department of Pharmacy at BMC.
- Provide support for all clinical drug studies conducted at BU/BMC.
- Responsible for the Receipt, Storage, Dispensing and Disposition of all researchrelated drug products.
- Ensure the investigational products are used appropriately to maximize study participant safety and mitigate any unnecessary risks.
- Ensure compliance with applicable regulatory and protocol requirements regarding the use of investigational products.
- Provide additional support to study teams related to research (randomization, drug accountability and disposition, blinding/unblinding, etc.)

Who staffs the IPS?

Stephen Zalewski, PharmD, CCRC

Husam Dennaoui, PharmD





Michael Camuso, PharmD

Valerie Nguyen, PharmD

Alexandra Cruzado, CPhT







Where is IPS Located?

Boston Medical Center

Investigational Pharmacy Service (ME-B378)

840 Harrison Ave

Boston, MA 02118

Phone: (617) 638-6774 Fax: (617) 638-6748

Email: <u>IPS@BMC.org</u>



What is a Drug?

FDA definition of Drug –

- A substance recognized by an official pharmacopoeia or formulary.
- A substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.
- A substance (other than food) intended to affect the structure or any function of the body.
 - ✓ Prescription medications
 - ✓ Over-the-counter (OTC) drugs
 - ✓ Vitamins

- ✓ Nutraceuticals
- ✓ Vaccines
- ✓ Diagnostic

- ✓ Contrast agents
- \checkmark Herbal remedies
- ✓ Sample medications

What is an Investigational Drug?

A drug that is being studied and that has not yet received permission from the U.S. Food and Drug Administration to be legally marketed and sold in the United States.

- New drug or already approved
- New strength or combination
- New dosage form
- New manufacturer (new generic version

- New route of administration
- New disease
- New population
- Investigational use of a commercial product

What Type of Studies does IPS Handle?



How are these Studies Funded?



What is the Value of Research?

- **Revenue** Grants and contracts provide direct and indirect revenues to the institution.
- **Cost Avoidance** A subject that qualifies to participate in a study may receive study drugs and other services provided by the sponsor, reducing the impact on the healthcare system.
- Recognition Intangible value of being recognized as a leader in research, with access to the latest drugs currently in development.
- Altruism Contributing to generalizable body of knowledge for society.

Why do we do what we do?

How do we do what we do?



Joint Commission on the Accreditation of Healthcare Organizations (JCAHO)

- A private, nonprofit organization whose mission is to continuously improve the safety and quality of care provided to the public; it does this through the provision of health accreditation and related services that support performance improvement in health care organizations.
- Joint Commission MM.06.01.05
 - Standard: The hospital safely manages investigational medications.
 - Element of Performance: The hospital's written process for the use of investigational medications specifies that the pharmacy controls the storage, dispensing, labeling, and distribution of investigational medications.

What FDA Requirements Apply?

- <u>§312.6</u> Labeling of an investigational new drug.
- §312.7 Promotion of investigational drugs.
- §312.8 Charging for investigational drugs under an IND.
- §312.59 Disposition of unused supply of investigational drug.
- §312.60 General responsibilities of investigators.
- §312.61 Control of the investigational drug.
- §312.62 Investigator recordkeeping and record retention.
- §312.68 Inspection of investigator's records and reports.
- §312.69 Handling of controlled substances.

What Regulations and Guidelines Apply?

- Federal (FDA, NIH, NCI)
- State (DPH) and Local Regulations
- Hospital Policies and Procedures (JCAHO, ASHP)
- USP 797 (sterile), 795 (nonsterile) and 800 (hazardous) guidelines

What International Guidelines Apply?

- ICH International Conference on Harmonisation
- GCP Good Clinical Practice
- **GDP Good Documentation Practice**
 - ALCOA
 - Attributable
 - Legible
 - Contemporaneous
 - Original
 - Accurate

What IPS Policies and Procedures Apply?

- 13_90_110 Investigational Pharmacy Service Protocol Initiation
- 13_90_120 Investigational Pharmacy Service Study Close-out
- 13_90_210Receipt And Storage Of Investigational Products
- 13_90_220 Hospital Admissions For Subjects Participating In A Clinical Trial
- 13_90_230 Authorized Prescribers Of Investigational Products
- 13_90_310 Accountability Records For Investigational Products
- 13_90_320 Chain of Custody and Transfer of Investigational Products
- 13_90_410 Destruction Disposition Of Investigational Products
- 13_90_510 Investigational Pharmacy Service Quality Assurance
- 13_90_610 Good Clinical Practice Training
- 13_90_710 Investigational Pharmacy Service Costs & Fees
- 13_90_720Billing Of Investigational Products Used In Clinical Research Studies

What Services Does IPS Offer?

- Protocol Review and Editing
- Study Start-Up/Close-Out
- Institutional Logistics and Operations
- Inventory Control
- Storage temperature monitoring
- Drug Information
- Assist with database maintenance (Vestigo, EPIC)
- Pharmacy Binders

- Dispensing and Accountability
- Randomization and Treatment Assignments
- Blinding
- Compounding
- Repackaging
- Collaborating with monitors and auditors for site and remote visits.
- Providing tours for site qualification visits
- IRB membership

When should we contact IPS with a new project?



As Early As Possible!

IPS Involvement with a New Project

- Review of protocol/draft to determine feasibility
- Determine the scope of the project
- Inpatient vs Outpatient vs Ambulatory Infusion Center
- Clinic setting vs GCRC
- 24h/7d enrollment
- Nursing/Pharmacy training needs
- IPS cost analysis
- Project timelines



I didn't realize just how much was involved!

Preparing a IPS Budget

- IPS Protocol Planning Worksheet
- IPS Budget Worksheet
- IPS Budget Agreement

IPS Protocol Planning Worksheet

IPS PROTOCOL	PLANNING WORKSHEET	
Sponsor: Sponso	r s Protocol Number:	
Protocol Title:		
Investigator:	Phone:	Pager :
Department:	Fund Management (BU or BMC)	
Study Coordinator:	Phone:	Pager :
<u>Items yoʻu re submitting:</u>		
Protocol Summary Other:		
Information you need from IPS: Cost Estimate - Timeline: Schedule a pre-study visit or planning meet Other:	ing (Explain):	
<u>Tell us about the study:</u>		
How many subjects are you planning to enroll? Anticipated start date: Overall study duration:		
Where will subjects be seen or dosed?		
Has the study been submitted to IRB?	If so, provide #:	
IF KNOWN, does the sponsor require any specia	alized training sessions, webinars, etc?	
Do any medications or supplies need to be pure	chased?	
What medications/supplies will be provided free	ee through sponsor?	
Any special manufacturing/compounding/form	ulation needed?	
Any special packaging requested?		
Will IPS be involved with other sites (distribution	on, coordination, etc)?	
Any other important information?		

IPS Budget Worksheet

	INVES	TIGATIONAL	PHARMACY	SERVICE	(IPS) PROTOCOL BUDGET	WORKS	HEET
Est. Start D	ate:				Prescription Complexit	y: _{Level}	(see Section A)
Duration:			months		Number of Rx s/Study Visi		R⁄x s
Target Enro	ollment:		subjects	Num	nber of Visits/Treatment Arn	n:	visits/Arm
the followin STUDY Me Stuc IPS	ng: / INITIATION eting with st dy Protocol Bin	FEE (~12 hours udy personnel-	5) — both in-ho	use and spo	dy that includes but is not lin		16 hour = \$xxx.xx (rate \$xx/hr) Fixed fee.
 Arra Creation STUDY Fination Mean Control 	anging for sh ation of stuc (CLOSEOUT al accountab eting with st	ipment of stud y file(s) and ass FEE (~4 hours) ility logs, udy monitor fo m maintenance	y drug and de sociated drug r determinati	etermining file(s) in th	space requirements le IPS computer system disposition of study materia	ls	
DISPENSIN	G FEES- The	ese fees vary an	nd depend on	the type of	f dispensing:		Dispensing fee per
	Level 1	Unit of Use d	ispensing (inp	atient and	ringes, vials for home use outpatient) Standard of Care (SOC)	30min	enrollment A x rate x B x C = \$ xxx.xx Dispensing fee for entire study A x rate x B x C x D = \$ xxx.xx Variable fee based
A	Level 2	IV doses (che Doses requiri LVP, IVPB or s Controlled Su Complex acco May include	ng reconstitu syringes ubstances puntability do	tion cumentatio		45min	
	Level 3	More comple	ex than basic I	evel 1&2 p.		60min	
	Level 4	To be determined by the protocol, eg Rx-specific blinding, compounding, etc.					on enrollment.
В		Number of pr		-			
С		Number of St	udy Visits/Tre	eatment Ar	m		4
D		Number of su	-				
 Mai Ord Mee 	intaining inv ering necess eting with st	udy monitors a	nd storage are nd disposal of and auditors	eas expired or	pent: unused supplies tocol is amended		0.5 hr/month x rate = \$xxx.xx/month x X months = \$xxx.x Variable fee based study duration.
FEES FOR S	PECIAL SERV	/ICES-					TBD
	domization	schedules g procedures		•	Prepacking Compounding		Variable fees study

IPS Budget Agreement

INVESTI	GATIONAL PHAR	MACY SERVICES	(IPS) B	UDO	GET AGRE	EEM	IENT
Sponsor Name							
Protocol Number				IRB	Number		
Protocol Title							
Principal Investigator			Phone				Pgr
Study Coordinator			Phone				Pgr
Department/Division			BU Manag	ged	IO#		
Funding Agency			BMC Managed AU # ACT #		ACT #		
			Provided Estimates Entire Study			tire Study	
STUDY INITIATION/CLC	SEOUT FEES						
MONTHLY ADMINISTR	ATIVE FEES						
DISPENSING FEES		\$xx.xx/Rx Disp'd					
FEES FOR SPECIAL SERV	VICES						

TOTAL

Fixed Fees will be billed as soon as the study agreement is executed. Dispensing Fees and Monthly Administrative Fees will be billed quarterly. Fees for Special Services will be billed quarterly as they occur.

IPS Charges are estimates based on the information provided prior to study initiation and may be reviewed and adjusted annually.

All payment is due day of invoice and expected within 45 days of invoice. Failure to pay within 120 days will result in discontinuation of IPS support. No study drugs will be dispensed by IPS for new enrollments. IPS handling of study drug for existing subjects will be cease as soon as it is safely feasible. The investigator will not be permitted to initiate any other trial with IPS support for a period of time to be determined by the Department of Pharmacy.

IPS signature: _____ Date: _____

Please contact IPS Manager, Stephen Zalewski at ext. 85957 or via email at <u>Stephen.Zalewski@bmc.org</u> if you have any questions or comments.

PI Approval Signature: _____ Date: ______ In order for IPS pharmacy to proceed please sign and return the fee schedule to IPS Pharmacy.

What is Meant by "IPS Readiness"?

- Protocol Documents
- IPS Budget
 - IPS will not begin working on an investigational protocol until the budget agreement is signed by the PI.
- IRB Approval
- Training and Delegation of Authority Logs
- IXRS access
- Protocol-specific prescription templates.
- Authorized Prescribers List
- Site logistics

<u>I have</u> <u>enrolled my</u> <u>first</u> <u>participant.</u>





<u>3 critical documents</u>

- 1. Prescription Paper template or EPIC
- 2. Informed Consent Form
- 3. Randomization-Enrollment Confirmation

<u>IPS Rx</u> Template Boston Medical Center / Investigational Pharmacy Service (IPS) ME-8378 840 Harrison Ave. Boston, MA 02118 Tel#: (617) 638-6774 Pax#: (617) 638-6748 Pager # 2809

Investigational Drug Prescription Sponsor: PHARMA COMPANY Protocol: abc123 IRB: H-88888 --- PROTOCOL TITLE ---PE DOCTOR, MD Authorized Prescribers: DOCTOR, MD xS####, pgr: #### Saure, pgr. nure NPI: ******* NPI: postappurap Study Coordinator: NURSE, x8#### Subject ID#: Subject's Name: Subject's Address: ______ City: _____ State: ____ ZIP: _____ MRN: Allergies: Study Drug: DRUG NAME/Placebo 200 mg/0 mg tablet (120 tabs/bottle) Date & Time # of Visit Directions Authorized Prescriber Signature Date Needed Bottles Signature page of ourrent informed Consent sent to IPS Take 1 tablet by mouth twice ___ Dey 1 daily (in the morning and evening) _____ ____ Dey 7 _____ 11_ -----____ _____ ____ ------____ ____ _____ 11_ _____

Comments:

V 06-APR-2016

Communication between the study team and IPS is the key to success!

• Scheduling subject, monitor, and sponsor visits

elete e	Sch	oointment eduling Assistant Show	Skype Meeting	Meeting Notes Meeting Notes	Cancel Invitation	Options •	Tags	Zoom	
	iven't sent t	his meeting invitat		Meeting Notes	Attenuces			20011	
	To	Investigational F	harmacy Servic	es					
Send	Subject	GILEAD GS-US-560-	-1357 (4420/TTR)	ł					
	Location								Rooms
	Start time	Thu 5/25/2017		2:30 PM		All day e	vent		
	End time	Thu 5/25/2017		2:30 PM	•				

Communication between the study team and IPS is the key to success!

- Scheduling subject, monitor, and sponsor visits
- Site Initiation Visits and Training Sessions
- Study Close-out Visits
- IRB outcome letter and updates new amendments, enrollment suspensions, protocol extensions and terminations.
- Changes to the BU or BMC account numbers

FAQ – Patients admitted to the hospital while on a clinical trial

Patient admitted to:

- 1. BMC while on a BU/BMC study
- 2. BMC while on a study from another institution
- 3. Another hospital while on BU/BMC study

How Can Pharmacists/IPS Assist?

- Admitting/treating physician is responsible Pharmacist on duty can assist
- Attempt to identify and contact the Principal Investigator to determine what the study is about and what investigational drugs are being used.
- Determine if the hospital admission (Serious Adverse Experience SAE) is related to clinical study or study drug.
- Assist with emergency unblinding if necessary
- Ascertain if the study drug will be continued while admitted
- Obtain study drug if necessary

FAQ

- Research with FDA-approved, commercially available drugs
- Temperature monitoring chain of custody
- Blinding investigational products and compounding matching placebos
- Final Drug Disposition
- Archiving study records

In Summary – Why use IPS?

- Required by hospital policy
- Budgeting
- Avoid possible obstacles and pitfalls
- Participant Safety
- Protocol Compliance
- Operational Issues
- Drug Supplies and Handling



Thank you!

Any Additional Questions?